| Publisher's Note: Join the Fierce Biotech team at the Fierce Biotech Summit on September 19-20 in Boston. This two-day event focuses on innovation in biopharma and highlights the companies that are pioneering innovative ideas and new technologies to drive the industry forward. Learn more here. | |
|
ESMO: GSK keeps the faith in anti-TIGIT plans; it's 'not always about being first' ESMO: Adding bempeg to Opdivo lowered response rate in Bristol Myers-Nektar failed cancer trial After flunking studies last year, Allakos’ failed phase 3 EoDyssey sinks gastrointestinal program Cannabinoid-focused drugmaker InMed blames 'recessionary pressures' for exiting wellness sector 'The Top Line': Sarepta's DMD trial set to regain momentum, Illumina's quest for Grail sees opposing results Here we go again: FDA opens up emergency authorizations to monkeypox tests ESMO: Merck's Keytruda-Lenvima flop hands Novartis-BeiGene, Hengrui a brighter liver cancer future Former J&J executive settles with company in workplace discrimination lawsuit DHS reverses Trump-era 'public charge' immigration healthcare rule Chutes & Ladders—Homology taps new CEO after pipeline restructure Fierce Pharma Asia—Astellas-Seagen, Eisai-Merck, BeiGene-Novartis, Hengru share new cancer data at ESMO Featured Story | By Max Bayer Four months after the latest trial failure for Roche’s tiragolumab, GSK is still pushing ahead with its own anti-TIGIT inhibitor, bullish that plenty of opportunities remain for the next-gen therapy. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor The European Society for Medical Oncology (ESMO) congress could have been a victory lap for Bristol Myers Squibb and Nektar Therapeutics, the moment when a bold bet delivered clinical data to upend the immuno-oncology space. Instead, the partners were left to sift through the wreckage of a failed trial that suggested bempegaldesleukin may make Opdivo less—not more—effective. read more By Nick Paul Taylor Allakos has achieved an undesired hat trick. Across three phase 3 trials, the biotech has now significantly reduced levels of a troublesome white blood cell without improving symptoms, driving it to rethink the development of an anti-Siglec-8 antibody that was once among the hottest prospects in biotech. read more By James Waldron Jumping into the health and wellness sector once seemed like an easy win for some pharma companies, but the tough times are increasingly extending beyond biotech. That certainly seems to be the case for InMed Pharmaceuticals, which is backing out of the wellness area less than a year after the Canadian drug developer acquired cannabinoid company BayMedica. read more By Teresa Carey This week on "The Top Line," we discuss Sarepta's phase 2 Duchenne muscular dystrophy clinical trial that was green-lit earlier this week after a clinical hold in June. We also chat the opposing results on either side of the pond for Illumina quest for Grail. read more By Conor Hale Using what was once a lesser-known regulatory option made world famous by the COVID-19 pandemic, the FDA has granted its first Emergency Use Authorization to a diagnostic test for monkeypox as cases continue to spread worldwide. read more By Angus Liu A surprise Keytruda failure in liver cancer spells good news not just for established immunotherapy player Roche but also for potential contenders Jiangsu Hengrui Pharma and a partnership between BeiGene and Novartis. read more By Zoey Becker In 2020, Gina Bilotti filed a complaint against her former employer, Johnson & Johnson, alleging discrimination and retaliation spanning back three years. The complaint details numerous discriminatory practices by multiple executives at the company, painting a picture of a "boys club" culture. The lawsuit has now been dismissed as the parties reached an "amicable resolution." read more By Robert King The Biden administration issued a final rule that reverses the Trump-era "public charge" regulation, which can impact immigration healthcare. read more By Gabrielle Masson,Max Bayer Arthur Tzianabos, Ph.D., is stepping down from his role as Homology’s CEO, handing the reins over to Albert Seymour, Ph.D. read more By Angus Liu At ESMO congress 2022, Seagen, Astellas and Merck showed how Padcev and Keytruda contributed to a combo in previously untreated bladder cancer. Three sets of PD-1 liver cancer data by Merck and Eisai, BeiGene and Novartis and Jiangsu Hengrui Pharma, showed different results. And more. read more Resources Sponsored by: Genpact Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: ReachBio | The Cell Biology Experts™ How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ZS ZS helps life sciences companies shape the future of medicine by turning healthcare data into transformative insights. Discover the power of R&D innovation Sponsored by: DocuSign Today’s healthcare systems are adapting to an ever changing landscape with declining margins, M&A pressures, and the need for staff flexibility due to shortages. Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: Blue Matter, strategic consultants in the life sciences This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Unlearn TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Ferma.AI, a Product of ZoomRx Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: JLL Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Events European Healthcare Compliance Certificate Program Septemeber 19-23, 2022 Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Free Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Drug Development Boot Camp® 2022 November 16-17, 2022 |
